Yale scientists inject nicotine to unlock Smoking's grip
NCT ID NCT05176418
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This completed early-phase study at Yale tested how the dose and speed of nicotine delivery affect its addictive potential and its ability to reduce smoking urges. Twenty daily smokers received IV nicotine pulses at different doses and rates to mimic cigarette smoking. The goal was to better understand what makes smoking so addictive.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NICOTINE DEPENDENCE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
VA Healthcare System
West Haven, Connecticut, 06516, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nicotine (given intravenously)
What this could lead to
If successful, this research could help understand how nicotine delivery methods influence addiction, potentially guiding future smoking cessation strategies.
What could go wrong
This is a very small, early-phase study (20 participants) that uses IV nicotine, not real smoking. Results may not translate to real-world smoking behavior or lead to treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.